.png){kind=small}
Boswellia serrata Extract
65% / 70% Boswellic Acids --- BosFlex™ Grade
Botanical Source :
Boswellia serrata Roxb. --- oleo-gum resin \| Madhya Pradesh & Chhattisgarh, India
Standardisation :
65% total boswellic acids (AKBA ≥ 10%) \| 70% total boswellic acids (AKBA ≥ 15%). HPLC-verified at both 210 nm and 254 nm.
.png)
Mechanism of Action
Boswellic acids --- principally AKBA --- are potent selective inhibitors of 5-lipoxygenase (5-LOX), the enzyme responsible for leukotriene (LTB4) synthesis. This mechanism is distinct from NSAIDs (which target COX-1 / COX-2) and therefore carries a gastric-protective profile, making Boswellia suitable for patients who cannot tolerate conventional anti-inflammatory agents. Additional mechanisms include NF-κB suppression, TNF-α / IL-1β / IL-6 downregulation, NLRP3-inflammasome pathway inhibition, and MMP-3 / MMP-9 inhibition --- the last of which protects cartilage matrix from proteolytic degradation in osteoarthritis.
Top 3 Applications
1. Nutraceuticals / Joint Health --- Osteoarthritis & Mobility Formulations
A 2024 multicentre, double-blind, randomised, placebo-controlled trial (Majeed et al., Front Pharmacol 2024;15:1428440) confirmed that standardised Boswellia serrata extract shows improvements in knee osteoarthritis within five days at 150--300 mg twice daily. A meta-analysis of 7 RCTs (545 patients) confirmed significant WOMAC-pain reduction vs placebo, ibuprofen, and glucosamine. BosFlex™ 65/70% ensures consistent AKBA delivery above the clinical threshold. \[Front Pharmacol 2024 (PMC11291344)\] \[7-RCT meta-analysis (PMC7368679)\]
2. Pharma / Anti-Inflammatory --- IBD, Asthma & Pharmaceutical-Grade Ingredient
Boswellia serrata extract is recognised within European phytomedicine monographs. Clinical evidence supports efficacy in Crohn\'s disease, ulcerative colitis, and asthma through leukotriene-pathway modulation. Unlike NSAIDs, it carries no GI-erosion profile.
3. Sports Nutrition / Recovery --- Exercise-Induced Inflammation Resolution
​Selective 5-LOX inhibition targets exercise-induced inflammation without the muscle-protein-synthesis suppression associated with NSAIDs. A growing evidence base supports joint-integrity maintenance under high mechanical load.
Specification & Quality Benchmarks
Solvent system: food-grade ethanol (no chlorinated solvents).
Boswellic acids (HPLC): ≥ 65% or ≥ 70% total; AKBA ≥ 10% (65 grade) or ≥ 15% (70 grade).
β-boswellic acid profile: documented in-house.
Heavy metals: Pb ≤ 1.0 ppm \| Cd ≤ 0.3 ppm \| As ≤ 1.0 ppm \| Hg ≤ 0.1 ppm.
Pesticide residues: USP \<565\> / EU MRL-compliant.
Microbial: TPC ≤ 10³ CFU/g; E. coli & Salmonella absent.
Shelf life 24 months at ≤ 25 °C.
Synergy Map — Formulation Pairings
With Curcumin phytosome --- dual anti-inflammatory pathways (5-LOX + COX-2/NF-κB) = flagship joint-health combination.
With UC-II undenatured collagen --- cartilage structural support + inflammation resolution.
With Ashwagandha root --- joint + stress-resilience dual positioning for 40+ demographic.
With Ginger + Black Pepper (piperine) --- Ayurvedic anti-inflammatory trio with piperine-enhanced bioavailability.
With Gotu Kola (Centella asiatica) --- classical Ayurvedic medhya pair.
Formulation Intelligence
Typical oral dose: 150--300 mg extract BID (300--600 mg/day).
Formats: capsule, tablet, softgel, topical cream/gel (1--5% w/w), phytosome complex for enhanced bioavailability.
pH stability: 4.0--8.0.
Solubility: low water solubility (resin origin) → phytosome or lecithin complex recommended for bioavailability (7× AKBA AUC observed in phytosome form).
Colour: cream-to-pale-yellow powder; near-odourless at finished-product level.
Buyer's Quick-Qualify
MOQ: 25 kg. Free sample 50 g with TDS, CoA, and AKBA HPLC chromatogram.
Lead time: 4 weeks standard; 5--6 weeks for AKBA-enriched or phytosome complexed grades.
Custom grades: 40%, 65%, 70%, 90% total boswellic acids; AKBA ≥ 30% research grade
Topical-grade micronised powder and decolourised grade available.
Export markets served: US, EU, UK, Japan, Australia, GCC.
Market & a Snapshot
​Global joint-health supplement market: \~USD 13 B (2024), CAGR \~7%. Boswellia is a top-3 joint ingredient after glucosamine and turmeric. Regulatory: US --- GRAS-self-affirmed for several grades; EU --- HMPC Community Herbal Monograph covers traditional use; Health Canada NHP-licensed; India --- AYUSH-classical.
Emerging Applications
Phytosome / lecithin-complex Boswellia (7× bioavailability) is the premium format for 2025+ joint launches. AKBA-enriched \"next-gen\" grades (AKBA ≥ 30%) emerging for pharmaceutical-grade IBD research. Topical NSAID-alternative gels gaining share in geriatric and sports-recovery categories.
Key Scientific References
-
Majeed A et al. Front Pharmacol 2024 (PMC11291344)
-
Yu G et al. meta-analysis 2020 (PMC7368679)
-
Boswellia bench-to-bedside 2025 (PMC12669112)
Contact & Next Steps
PHELBA Life Sciences · Technical Data Sheets, Certificates of Analysis, HPLC
chromatograms, stability studies, and 50–100 g free samples are available on
request for any SKU.
Website
Markets Served
US, EU, UK, Japan, Australia, GCC, ASEAN
All extracts manufactured at our cGMP- and ISO 9001:2015-certified partner facilities in India.
​
FSSAI- and HACCP-licensed. Halal and Kosher certification available on request. Organic (NPOP / NOP / EU-Organic) variants available on select SKUs.